Published Date: 29 Nov 2024
Patterns of blood-brain barrier disruption varied between children and adults
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
A promising medication could slow brain tumors in children.
2.
Why Did Rare Cancer Shrink on Its Own?
3.
Study finds primary-care doctors often overlook prostate cancer risk in Black men
4.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
5.
Study: For predicting breast cancer, AI performs better than traditional risk models.
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment
3.
Hepatocellular Carcinoma: Emerging Trends and Innovations in Diagnosis and Management
4.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
5.
Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
3.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Efficient Management of First line ALK-rearranged NSCLC - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation